{"success":true,"data":{"pressRelease":{"id":"167247","rtpr_id":"nGNX2H6hQ1-20261013","ticker":"TLRY","exchange":"NASDAQ","all_tickers":["TLRY"],"title":"Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets","author":"Globe Newswire","published_at":"2026-10-13T11:00:01.118Z","article_body":"CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a\nglobal leader in medical cannabis research, cultivation, production, products\nand distribution and a division of Tilray Brands, Inc.\n(https://www.globenewswire.com/Tracker?data=9j-DX3dsfKANgJxZWkGdsrN6wC0I9eCPpyjkcJIrMKnCwoiJVeJHjtL3m2ipUNU8zZ9ejVnRPoN0WTr4iWhwvTalIGmsIpgeOh0iTyIvVHY=)\n(“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory\nmilestone in Europe: INFARMED, Portugal’s National Authority of Medicines\nand Health Products, has approved the quality control laboratory at Tilray\nMedical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct\nmicrobiological and chemical/physical testing in-house. The approval gives\nTilray Medical greater command over critical quality testing, accelerates\nproduct release capabilities, and strengthens its Portugal facility as a\nstrategic launchpad for pharmaceutical-grade medical cannabis supply across\nregulated international markets.\n\nWith this authorization, Tilray Medical further differentiates its European\nproduction platform by embedding advanced testing capabilities directly within\nits EU-GMP infrastructure. The approval reinforces Cantanhede as a strategic\ncenter for cultivation, production, testing, and international supply, and\ncomes as demand for trusted, pharmaceutical-grade medical cannabis continues\nto grow across regulated markets.\n\nRajnish Ohri, President, International, Tilray Brands, stated: “As regulated\nmedical cannabis markets continue to mature, the companies best positioned to\nlead will be those that combine pharmaceutical-grade quality, regulatory\ndiscipline, and reliable global supply at scale. Tilray has built one of the\nworld’s leading EU-GMP-certified medical cannabis operations, and this\napproval further strengthens our platform in Portugal by bringing advanced\nquality testing closer to cultivation and production. It gives us greater\nspeed, control, and flexibility across our international supply chain while\nreinforcing the infrastructure and technical expertise required to serve\npatients, physicians, pharmacies, and commercial partners with trusted medical\ncannabis products in high-standard markets around the world.”\n\nFor Tilray Medical, bringing critical quality testing in-house creates an\nimportant operational advantage in the fast-evolving global medical cannabis\nmarket. By reducing reliance on third-party testing for flower lots, the\nCompany can lower batch-release costs, shorten testing timelines, and move\nproduct more efficiently from harvest to release and sale. These capabilities\nstrengthen Tilray Medical’s ability to manage supply across key\ninternational markets, including Germany, the United Kingdom, Poland, Italy,\nand other regulated medical cannabis markets, while supporting more reliable\naccess for patients and commercial partners.\n\nThis milestone builds on Tilray Medical’s broader international momentum,\nincluding increased output at its EU-GMP-certified Portugal facility and the\nexpansion of Tilray Medical-branded cannabis medicines in the United Kingdom\nthrough Lyphe Clinic and Lyphe Dispensary. Together, these initiatives\nstrengthen Tilray Medical’s position as a trusted global medical cannabis\nsupplier with the infrastructure, regulatory expertise, and commercial reach\nto compete in high-standard pharmaceutical markets.\n\nAbout Tilray Medical \nTilray Medical is dedicated to transforming lives and fostering dignity for\npatients in need through safe and reliable access to a global portfolio of\nmedical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX,\nand Broken Coast. Tilray grew from being one of the first companies to become\nan approved licensed producer of medical cannabis in Canada to building the\nfirst GMP-certified cannabis production facilities in Europe, first in\nPortugal and later in Germany. Today, Tilray Medical is a global leader in\nmedical cannabis, having served patients in more than 20 countries across five\ncontinents.\n\nFor more information on Tilray Medical, visit Tilray Medical Europe\n(https://www.globenewswire.com/Tracker?data=9j-DX3dsfKANgJxZWkGdsp6Ok46iDfu2GjOvjw3vPXmAZHrgPUP9TY-8NhKCPHojHVCP9YpA5FrszdPUOpfUeXJwG872RTKESOhFX4dcKfk=), Tilray\nMedical Canada\n(https://www.globenewswire.com/Tracker?data=9j-DX3dsfKANgJxZWkGdsjekYXUMXfhsLtehhVV3WelnUdWOr7Frxs-geZZJHN7Ml7D3Thd0TfvMnadoB0tNQ25vZRYTZxfgFxKRufl_YtB88qxxBVrhErUsuhPaAB1kfM3JBBFmcQXpIKgAtQdECt32vb75zHVWyJ08pOYox2tGnlqS1lPjndyjAjHQy0YcYcN0OKx96pvcnox2fHQ7UufVZnke6UNVADAcciCXnRCIzJA_lvbUHTSqyrh_AGp_B6tZFk42K2g4Aoz1QdQpXmYqQP-Vl6MwDaAJAF-kQdiZP1BWy72JnDjEnBMSx5KCFc-3HU2qQRLw1YULI9WFCdjKTyYEZ2Yw5VfhyCtQ0PFQ4xtb2_b4uhGCcxKMCxpqOQzg9zra2MD-7L-OK4elwm4Z79qIBxWyjLQBRigLnSW9Tg4cqdEpO9M8BXthtSWOzSF5UCqZm7qIYgshgjWrQcE4TGQJFKxT7hmjfitO7E3Tvu2EA6MMQQqzhl16zbp1), Tilray\nMedical Australia-New Zealand\n(https://www.globenewswire.com/Tracker?data=9j-DX3dsfKANgJxZWkGdskgemA1t9wOUQqutjYU4H6gXec45eIsLhrUXvD_YZ8msYDSun7hcHTvSWt1A579-uJ2VtHoBKgcR0CTTrp5hFqEtF1KsQsBgWPRbEYVds1ga)\nand Solana.pa\n(https://www.globenewswire.com/Tracker?data=eLPJDqIE7sWOLMABCsDK7v0SavsG3JEGlaaE1TPfoiTEIvfbafIXvKenD10yS233gTbxVTr4qJzeoDyLXI67WQ==)\nin Panama.\n\nAbout Tilray Brands \n\nTilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading\nglobal lifestyle and consumer packaged goods company with operations in\nCanada, the United States, Europe, Australia, and Latin America that is\nleading as a transformative force at the nexus of cannabis, beverage,\nwellness, and entertainment, elevating lives through moments of connection.\nTilray’s mission is to be a leading premium lifestyle company with a house\nof brands and innovative products that inspire joy and create memorable\nexperiences. Tilray’s unprecedented platform supports over 40 brands in over\n20 countries, including comprehensive cannabis offerings, hemp-based foods,\nand craft beverages.\n\nFor more information on how we are elevating lives through moments of\nconnection, visit Tilray.com and follow @Tilray on all social platforms.\n\nForward-Looking Statements\n\nCertain statements in this communication that are not historical facts\nconstitute forward-looking information or forward-looking statements\n(together, “forward-looking statements”) under Canadian and U.S.\nsecurities laws and within the meaning of Section 27A of the Securities Act of\n1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as\namended, that are intended to be subject to the “safe harbor” created by\nthose sections and other applicable laws. Forward-looking statements can be\nidentified by words such as “forecast,” “future,” “should,”\n“could,” “enable,” “potential,” “contemplate,” “believe,”\n“anticipate,” “estimate,” “plan,” “expect,” “intend,”\n“may,” “project,” “will,” “would” and the negative of these\nterms or similar expressions, although not all forward-looking statements\ncontain these identifying words. Certain material factors, estimates, goals,\nprojections, or assumptions were used in drawing the conclusions contained in\nthe forward-looking statements throughout this communication. Forward-looking\nstatements in this communication include statements regarding the expected\nbenefits of the INFARMED approval, including reduced batch-release costs,\nshortened testing timelines, accelerated product release supply to\ninternational markets, and our intentions, beliefs, projections, outlook,\nanalyses, or current expectations. Many factors could cause actual results,\nperformance, or achievement to be materially different from any\nforward-looking statements, and other risks and uncertainties not presently\nknown to the Company or that the Company deems immaterial could also cause\nactual results or events to differ materially from those expressed in the\nforward-looking statements contained herein. For a more detailed discussion of\nthese risks and other factors, see the most recently filed annual information\nform of Tilray and the Annual Report on Form 10-K (and other periodic reports\nfiled with the SEC) of Tilray made with the SEC and available on EDGAR. The\nforward-looking statements included in this communication are made as of the\ndate of this communication and the Company does not undertake any obligation\nto publicly update such forward-looking statements to reflect new information,\nsubsequent events, or otherwise unless required by applicable securities laws.\n\nFor further information, please contact:\n\nMedia: news@tilray.com  \n\nInvestors: investors@tilray.com  \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2dbf85bb-5e30-4623-8f9b-931442240c05)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2H6hQ1-20261013","title":"Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets","author":"Globe Newswire","ticker":"TLRY","created":"2026-10-13T11:00:01.118Z","tickers":["TLRY"],"exchange":"NASDAQ","article_body":"CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a\nglobal leader in medical cannabis research, cultivation, production, products\nand distribution and a division of Tilray Brands, Inc.\n(https://www.globenewswire.com/Tracker?data=9j-DX3dsfKANgJxZWkGdsrN6wC0I9eCPpyjkcJIrMKnCwoiJVeJHjtL3m2ipUNU8zZ9ejVnRPoN0WTr4iWhwvTalIGmsIpgeOh0iTyIvVHY=)\n(“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory\nmilestone in Europe: INFARMED, Portugal’s National Authority of Medicines\nand Health Products, has approved the quality control laboratory at Tilray\nMedical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct\nmicrobiological and chemical/physical testing in-house. The approval gives\nTilray Medical greater command over critical quality testing, accelerates\nproduct release capabilities, and strengthens its Portugal facility as a\nstrategic launchpad for pharmaceutical-grade medical cannabis supply across\nregulated international markets.\n\nWith this authorization, Tilray Medical further differentiates its European\nproduction platform by embedding advanced testing capabilities directly within\nits EU-GMP infrastructure. The approval reinforces Cantanhede as a strategic\ncenter for cultivation, production, testing, and international supply, and\ncomes as demand for trusted, pharmaceutical-grade medical cannabis continues\nto grow across regulated markets.\n\nRajnish Ohri, President, International, Tilray Brands, stated: “As regulated\nmedical cannabis markets continue to mature, the companies best positioned to\nlead will be those that combine pharmaceutical-grade quality, regulatory\ndiscipline, and reliable global supply at scale. Tilray has built one of the\nworld’s leading EU-GMP-certified medical cannabis operations, and this\napproval further strengthens our platform in Portugal by bringing advanced\nquality testing closer to cultivation and production. It gives us greater\nspeed, control, and flexibility across our international supply chain while\nreinforcing the infrastructure and technical expertise required to serve\npatients, physicians, pharmacies, and commercial partners with trusted medical\ncannabis products in high-standard markets around the world.”\n\nFor Tilray Medical, bringing critical quality testing in-house creates an\nimportant operational advantage in the fast-evolving global medical cannabis\nmarket. By reducing reliance on third-party testing for flower lots, the\nCompany can lower batch-release costs, shorten testing timelines, and move\nproduct more efficiently from harvest to release and sale. These capabilities\nstrengthen Tilray Medical’s ability to manage supply across key\ninternational markets, including Germany, the United Kingdom, Poland, Italy,\nand other regulated medical cannabis markets, while supporting more reliable\naccess for patients and commercial partners.\n\nThis milestone builds on Tilray Medical’s broader international momentum,\nincluding increased output at its EU-GMP-certified Portugal facility and the\nexpansion of Tilray Medical-branded cannabis medicines in the United Kingdom\nthrough Lyphe Clinic and Lyphe Dispensary. Together, these initiatives\nstrengthen Tilray Medical’s position as a trusted global medical cannabis\nsupplier with the infrastructure, regulatory expertise, and commercial reach\nto compete in high-standard pharmaceutical markets.\n\nAbout Tilray Medical \nTilray Medical is dedicated to transforming lives and fostering dignity for\npatients in need through safe and reliable access to a global portfolio of\nmedical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX,\nand Broken Coast. Tilray grew from being one of the first companies to become\nan approved licensed producer of medical cannabis in Canada to building the\nfirst GMP-certified cannabis production facilities in Europe, first in\nPortugal and later in Germany. Today, Tilray Medical is a global leader in\nmedical cannabis, having served patients in more than 20 countries across five\ncontinents.\n\nFor more information on Tilray Medical, visit Tilray Medical Europe\n(https://www.globenewswire.com/Tracker?data=9j-DX3dsfKANgJxZWkGdsp6Ok46iDfu2GjOvjw3vPXmAZHrgPUP9TY-8NhKCPHojHVCP9YpA5FrszdPUOpfUeXJwG872RTKESOhFX4dcKfk=), Tilray\nMedical Canada\n(https://www.globenewswire.com/Tracker?data=9j-DX3dsfKANgJxZWkGdsjekYXUMXfhsLtehhVV3WelnUdWOr7Frxs-geZZJHN7Ml7D3Thd0TfvMnadoB0tNQ25vZRYTZxfgFxKRufl_YtB88qxxBVrhErUsuhPaAB1kfM3JBBFmcQXpIKgAtQdECt32vb75zHVWyJ08pOYox2tGnlqS1lPjndyjAjHQy0YcYcN0OKx96pvcnox2fHQ7UufVZnke6UNVADAcciCXnRCIzJA_lvbUHTSqyrh_AGp_B6tZFk42K2g4Aoz1QdQpXmYqQP-Vl6MwDaAJAF-kQdiZP1BWy72JnDjEnBMSx5KCFc-3HU2qQRLw1YULI9WFCdjKTyYEZ2Yw5VfhyCtQ0PFQ4xtb2_b4uhGCcxKMCxpqOQzg9zra2MD-7L-OK4elwm4Z79qIBxWyjLQBRigLnSW9Tg4cqdEpO9M8BXthtSWOzSF5UCqZm7qIYgshgjWrQcE4TGQJFKxT7hmjfitO7E3Tvu2EA6MMQQqzhl16zbp1), Tilray\nMedical Australia-New Zealand\n(https://www.globenewswire.com/Tracker?data=9j-DX3dsfKANgJxZWkGdskgemA1t9wOUQqutjYU4H6gXec45eIsLhrUXvD_YZ8msYDSun7hcHTvSWt1A579-uJ2VtHoBKgcR0CTTrp5hFqEtF1KsQsBgWPRbEYVds1ga)\nand Solana.pa\n(https://www.globenewswire.com/Tracker?data=eLPJDqIE7sWOLMABCsDK7v0SavsG3JEGlaaE1TPfoiTEIvfbafIXvKenD10yS233gTbxVTr4qJzeoDyLXI67WQ==)\nin Panama.\n\nAbout Tilray Brands \n\nTilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading\nglobal lifestyle and consumer packaged goods company with operations in\nCanada, the United States, Europe, Australia, and Latin America that is\nleading as a transformative force at the nexus of cannabis, beverage,\nwellness, and entertainment, elevating lives through moments of connection.\nTilray’s mission is to be a leading premium lifestyle company with a house\nof brands and innovative products that inspire joy and create memorable\nexperiences. Tilray’s unprecedented platform supports over 40 brands in over\n20 countries, including comprehensive cannabis offerings, hemp-based foods,\nand craft beverages.\n\nFor more information on how we are elevating lives through moments of\nconnection, visit Tilray.com and follow @Tilray on all social platforms.\n\nForward-Looking Statements\n\nCertain statements in this communication that are not historical facts\nconstitute forward-looking information or forward-looking statements\n(together, “forward-looking statements”) under Canadian and U.S.\nsecurities laws and within the meaning of Section 27A of the Securities Act of\n1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as\namended, that are intended to be subject to the “safe harbor” created by\nthose sections and other applicable laws. Forward-looking statements can be\nidentified by words such as “forecast,” “future,” “should,”\n“could,” “enable,” “potential,” “contemplate,” “believe,”\n“anticipate,” “estimate,” “plan,” “expect,” “intend,”\n“may,” “project,” “will,” “would” and the negative of these\nterms or similar expressions, although not all forward-looking statements\ncontain these identifying words. Certain material factors, estimates, goals,\nprojections, or assumptions were used in drawing the conclusions contained in\nthe forward-looking statements throughout this communication. Forward-looking\nstatements in this communication include statements regarding the expected\nbenefits of the INFARMED approval, including reduced batch-release costs,\nshortened testing timelines, accelerated product release supply to\ninternational markets, and our intentions, beliefs, projections, outlook,\nanalyses, or current expectations. Many factors could cause actual results,\nperformance, or achievement to be materially different from any\nforward-looking statements, and other risks and uncertainties not presently\nknown to the Company or that the Company deems immaterial could also cause\nactual results or events to differ materially from those expressed in the\nforward-looking statements contained herein. For a more detailed discussion of\nthese risks and other factors, see the most recently filed annual information\nform of Tilray and the Annual Report on Form 10-K (and other periodic reports\nfiled with the SEC) of Tilray made with the SEC and available on EDGAR. The\nforward-looking statements included in this communication are made as of the\ndate of this communication and the Company does not undertake any obligation\nto publicly update such forward-looking statements to reflect new information,\nsubsequent events, or otherwise unless required by applicable securities laws.\n\nFor further information, please contact:\n\nMedia: news@tilray.com  \n\nInvestors: investors@tilray.com  \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2dbf85bb-5e30-4623-8f9b-931442240c05)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-13T11:00:01.346026413Z","server_sent_at_ms":1791889201346},"received_at":"2026-10-13T11:00:01.396Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}